| Factors | Arm → | TChT | ChT | Distortion (→TChT) | Pat Nr → | Nr | % | Nr | % | Δ% | Weight | Dist% | Impact ↓ | 169 | 49,6% | 172 | 50,4% |
| General factors | | | | | | | | | Tumor size | Reverse | 11 | | 11,3 | | 2,7% | 100% | 2,7% | 3 grade | Reverse | 84 | 49,7% | 94 | 54,7% | 10,0% | 52% | 5,2% | Total | | | | | | 12,7% | | 7,9% |
| Chemotherapy | | | | | | | | | Number of ChT treated | Direct | 165 | 97,6% | 167 | 97,1% | 0,6% | 97% | 0,5% | 4 cycles | Direct | 151 | 89,3% | 146 | 84,9% | 5,3% | 87% | 4,6% | 1–3 cycles | Reverse | 14 | 8,3% | 21 | 12,2% | 47,4% | 10% | 4,9% | 0 cycles | Reverse | 4 | 2,4% | 5 | 2,9% | 22,8% | 3% | 0,6% | Total | | | | | | 76,0% | | 10,6% |
| TOTAL | | | | | | | | 18,5% |
| Immediate local response | | | | | | | | | No measurable disease | Direct | 52 | 30,8% | 46 | 26,7% | 15,1% | 29% | 4,3% | Measurable disease | Reverse | 117 | 69,2% | 126 | 73,3% | 5,8% | 71% | 4,1% | Total | | | | | | 20,9% | | 8,5% |
|
|